Melanoma Clinical Trials
Here are the 6 most popular medical studies for melanoma
Brachytherapy
Brachytherapy for Liver Tumors
This trial will study a new way to treat cancer using high-dose-rate brachytherapy (HDRBT), which is a type of radiation therapy. This therapy uses an iridium-192 (192Ir) isotope to administer a cytotoxic dose of radiation to a target lesion, and is not susceptible to heat sink effects.
Monoclonal Antibodies
CM24 + Nivolumab for Advanced Solid Tumors
This trial is testing a new cancer drug (CM-24) in combination with another drug (nivolumab) to see if it is safe and works well against advanced solid tumors, non-small cell lung cancer, and pancreatic cancer.
Popular filter options for melanoma trials
PD-1 Positive Clinical Trials
View 27 PD-1 positive medical studies.
Wnt Inhibitor
LGK974 for Malignancies Dependent on Wnt Ligands
This trial is testing a new drug called LGK974 to see if it is safe and effective in treating adults with cancer that has progressed despite standard therapy or for which no effective standard therapy exists.
Phase 3 Melanoma Clinical Trials
View 99 phase 3 melanoma medical studies.
Kinase Inhibitor
Combination Therapy for Melanoma
This trial is testing a combination of three drugs to treat melanoma that has spread and has a certain type of abnormal gene. One of the drugs is given as an IV infusion, and the other two are taken orally at home every day. The team will monitor how each participant is doing with the treatment during regular visits.
Radiation
IGIMRT Dosing Schedules for Cancer
This trial is studying two ways of giving high-dose radiation for treatment of cancer that has spread to bone, the spine, soft tissue, or lymph nodes. One way is 27 Gy in three fractions (3 days) and the other is 24 Gy in one fraction (1 day).
View More Melanoma Trials
See another 77 many medical studies focused on melanoma.
Frequently Asked Questions
Introduction to melanoma
What are the top hospitals conducting melanoma research?
When it comes to advancing the treatment options for melanoma, several top hospitals in the United States are leading the way. Memorial Sloan Kettering Cancer Center, situated in New York City, is at the forefront of melanoma research with nine active clinical trials and an astonishing 115 completed trials dedicated to this aggressive form of skin cancer. Since recording their first melanoma trial in 1991, Memorial Sloan Kettering has been instrumental in pushing boundaries and improving outcomes for patients.
In Boston, both Massachusettsf skin cancfor melanoma, several top hospitals in the United States are leading the way. Memorial Sloan Kettering Cancer Center, situated in New York City, is at the forefront of melanoma research with nine active clinical trials and an astonishing 115 completed trials dedicated to this aggressive form of skin cancer. Since recording their first melanoma trial in 1991, Memorial Sloan Kettering has been instrumental in pushing boundaries and improving outcomes for patients.
In Boston, both Massachusetts General Hospital and Dana Farber Cancer Institute are making significant contributions to melanoma research as well. Massachusetts General Hospital currently has seven ongoing clinical trials focused on melanoma while having accumulated a notable history of 86 previous studies since their first recorded trial back in 2003. Meanwhile, at Dana Farber Cancer Institute—another prominent medical institution within Boston's vibrant healthcare community—researchers are actively engaged in six clinical trials targeting melanoma after having conducted an impressive total of 64 such investigations since initiating their earliest recorded trial in 2004.
Further westward lies UPMC Hillman Cancer Center located in Pittsburgh—a formidable presence within the realm of melanoma research. With seven active clinical trials and a cumulative tally of 38 past investigations since they began exploring this field through their inaugural trial back in 2009, UPMC Hillman is committed to finding innovative solutions for patients facing this challenging diagnosis.
Lastly but certainly not least is MD Anderson Cancer Center based out of Houston—a renowned institution that has achieved breakthroughs across various cancers including melanoma. Currently conducting six active clinical trials pertaining to this specific malignancy while boasting a remarkable record of completing71 prior studies ever since embarking upon its initial investigation into treating melanoma backin1999,
These prestigious hospitals demonstrate exemplary dedication towards understanding and combating one of the deadliest formsof skin cancer- melonama.Their tireless effortsin pioneering treatmentsand conducting rigorousclinicaltrialsunderscore the necessity for continued research and collaboration. Through their collective achievements, they offer hope to countless patients while forging a path towards improved outcomes in the fight against melanoma
Which are the best cities for melanoma clinical trials?
When it comes to melanoma clinical trials, several cities are at the forefront of groundbreaking research. New York leads with 44 active trials focusing on Pembrolizumab, Botensilimab, PF-07799933, and other promising treatments. Boston follows closely behind with 36 trials investigating Pembrolizumab, DKY709, Botensilimab, among others. Los Angeles also emerges as a prominent location for melanoma clinical trials with 34 ongoing studies centered around Pembrolizumab, LXH254, Botensilimab. These cities offer individuals battling melanoma access to cutting-edge research that may pave the way for improved treatment options and potential breakthroughs in care.
Which are the top treatments for melanoma being explored in clinical trials?
Melanoma, a formidable foe in the world of cancer, spurs relentless research and development efforts. Prominent among the top treatments being explored in clinical trials are pembrolizumab and nivolumab. Pembrolizumab leads with seven active trials and an impressive history of 181 all-time melanoma trials since its inception in 2011. Nivolumab closely follows suit, exhibiting promising potential with four active studies and a noteworthy record of 165 all-time melanoma trials starting from 2010. Additionally, atezolizumab emerges as another contender for effective treatment, currently under investigation in two ongoing clinical trials alongside its involvement in 23 previous melanoma studies dating back to its introduction in 2012. As researchers push onward to uncover breakthroughs against this aggressive form of skin cancer, these innovative therapies offer renewed hope on the horizonf cancer, spurs relentless research and development efforts. Prominent among the top treatments being explored in clinical trials are pembrolizumab and nivolumab. Pembrolizumab leads with seven active trials and an impressive history of 181 all-time melanoma trials since its inception in 2011. Nivolumab closely follows suit, exhibiting promising potential with four active studies and a noteworthy record of 165 all-time melanoma trials starting from 2010. Additionally, atezolizumab emerges as another contender for effective treatment, currently under investigation in two ongoing clinical trials alongside its involvement in 23 previous melanoma studies dating back to its introduction in 2012. As researchers push onward to uncover breakthroughs against this aggressive form of skin cancer, these innovative therapies offer renewed hope on the horizon.
What are the most recent clinical trials for melanoma?
Recent clinical trials for melanoma have introduced promising advancements in treatment options. One such trial focuses on a combination therapy, aiming to determine its effectiveness and safety in patients with melanoma. Another study is investigating the potential benefits of DP CD8 TIL, which could offer new therapeutic possibilities. Additionally, researchers are exploring the efficacy of HFB200603 as a monotherapy for melanoma. These clinical trials mark significant progress towards improving outcomes and quality of life for individuals battling this challenging disease.
What melanoma clinical trials were recently completed?
Numerous clinical trials for melanoma have been recently completed, showcasing the continuous efforts to advance treatment options. Among these trials are the completion of a study on PRT1419 by Prelude Therapeutics in August 2021, and the conclusion of Bayer's trial on BAY2666605 in April 2021. Additionally, Hoffmann-La Roche wrapped up their investigation into RO7293583 in October 2020, while Cantargia AB finished their CAN04 trial in September 2020. These recent milestones signify progress towards finding effective therapies for melanoma patients and inspire hope for improved outcomes in the future.